ITOS iTeos Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ITOS

Price (delayed)

$9.36

Market cap

$334.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.72

Enterprise value

$136.48M

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of ...

Highlights
The quick ratio has soared by 163% YoY and by 6% QoQ
The company's net income has shrunk by 124% YoY and by 117% QoQ
The EPS has dropped by 123% year-on-year and by 118% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://iteostherapeutics.com
Peers: OMGA

Key stats

What are the main financial stats of ITOS
Market
Shares outstanding
35.78M
Market cap
$334.95M
Enterprise value
$136.48M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.56
Price to sales (P/S)
5.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.05
Earnings
Revenue
$66.5M
EBIT
-$58.1M
EBITDA
-$57.2M
Free cash flow
-$118.85M
Per share
EPS
-$1.72
Free cash flow per share
-$3.32
Book value per share
$16.72
Revenue per share
$1.86
TBVPS
$18.94
Balance sheet
Total assets
$677.64M
Total liabilities
$79.38M
Debt
$5.93M
Equity
$598.26M
Working capital
$590.91M
Liquidity
Debt to equity
0.01
Current ratio
21.94
Quick ratio
21.23
Net debt/EBITDA
3.47
Margins
EBITDA margin
-86%
Gross margin
100%
Net margin
-92.7%
Operating margin
-140.5%
Efficiency
Return on assets
-8.6%
Return on equity
-9.7%
Return on invested capital
-12.7%
Return on capital employed
-8.9%
Return on sales
-87.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ITOS stock price

How has the iTeos Therapeutics stock price performed over time
Intraday
-3.51%
1 week
-3.51%
1 month
0%
1 year
-53.55%
YTD
-52.07%
QTD
-14.52%

Financial performance

How have iTeos Therapeutics's revenue and profit performed over time
Revenue
$66.5M
Gross profit
$66.5M
Operating income
-$93.45M
Net income
-$61.64M
Gross margin
100%
Net margin
-92.7%
iTeos Therapeutics's net margin has shrunk by 181% QoQ
The operating income has shrunk by 129% YoY and by 43% QoQ
The company's net income has shrunk by 124% YoY and by 117% QoQ
The operating margin has plunged by 85% from the previous quarter

Growth

What is iTeos Therapeutics's growth rate over time

Valuation

What is iTeos Therapeutics stock price valuation
P/E
N/A
P/B
0.56
P/S
5.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.05
The EPS has dropped by 123% year-on-year and by 118% since the previous quarter
ITOS's P/B is 30% below its last 4 quarters average of 0.8
ITOS's equity is down by 6% YoY and by 4.1% from the previous quarter
ITOS's revenue has dropped by 85% year-on-year and by 23% since the previous quarter
The P/S is 12% higher than the last 4 quarters average of 4.5

Efficiency

How efficient is iTeos Therapeutics business performance
The return on sales has dropped by 182% since the previous quarter
The ROA has plunged by 127% YoY and by 126% from the previous quarter
The ROE has plunged by 123% YoY and by 120% from the previous quarter
The ROIC has dropped by 57% since the previous quarter

Dividends

What is ITOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ITOS.

Financial health

How did iTeos Therapeutics financials performed over time
The current ratio has surged by 168% year-on-year and by 7% since the previous quarter
The quick ratio has soared by 163% YoY and by 6% QoQ
iTeos Therapeutics's debt is 99% lower than its equity
iTeos Therapeutics's debt has increased by 32% YoY and by 9% QoQ
ITOS's equity is down by 6% YoY and by 4.1% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.